Daphne Karydas sold $690K of Mineralys Therapeutics (MLYS)

Executed Nov 13 2025, disclosed Nov 13 2025, the same day.

Value, as filed

$690K

15,000 sh across 2 lots

Executed

Nov 13 2025

the trade date, as filed

Disclosed

Nov 13 2025

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

DK Daphne Karydas Director profile →

Daphne Karydas (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $690K of MLYS (15,000 sh across 2 lots, as filed), executed Nov 13 2025.

The name

MLYS Mineralys Therapeutics, Inc. MLYS · Healthcare · 50 filings in 24 months ticker →

Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→